Abstract:Background Treatment effect of tumor necrosis factor α inhibitors (TNFi) in patients with spondyloarthritis (SpA) had been proved by plenty of studies that could remarkably eliminate symptoms, signs, and laboratory inflammatory manifestations [1,2]. Simultaneously, the treatment effect of TNFi on delaying radiographic progression in SpA was often reported [3,4], including magnetic resonance imaging (MRI) which has a high sensitivity on detecting the earliest inflammation [5]. Objectives A meta-analysis was performed to summarize the treatment effect of TNFi on MRI progression reflected by SPARCC score in SpA patients Methods Comprehensive search was conducted in the electronic databases of OVID Medline, OVID EMBASE and Cochrane library on Nov.27, 2018. All randomized controlled trials (RCTs) focused on MRI progression and disease activity in SpA patients treated with TNFi were included. Primary outcome was the Spondyloarthritis Research Consortium Canad (SPARCC) MRI scoring system, accompanied with or without other outcomes, including ankylosing Spondylitis Disease activity Score (ASDAS), Bath ankylosing Spondylitis disease activity index (BASDAI), Bath ankylosing Spondylitis functional index (BASFI), C-reactive protein (CRP). Data were pooled by mean differences (MD) with 95% confidence intervals (CI) and publication bias was assessed by funnel plot. Sensitivity analysis was performed to test the result robustness. Jadad scale was applied to assess the methodology quality of included trials. Two reviewers independently selected studies, extracted data, and assessed study quality. Results Totally 10 RCTs enrolled 1006 patients with high methodology were included. Compared with control group, TNFi significantly improved SPARCC score at sacroiliac joint (SIJ) (MD=2.84, 95% CI 2.43-3.25), SPARCC score of spine (MD=1.87, 95% CI 1.27-2.46), aSDAS (MD=0.96, 95% CI 0.71-1.20), BASDAI (MD=1.15, 95% CI 0.51-1.78), BASFI (MD=0.95, 95% CI 0.51-1.40), and CRP (MD=4.64, 95% CI 1.06- 8.23) in double-blind phase. Subgroup analyses by disease subgroup and individual TNFi showed treatment effect of TNFi on delaying MRI progression was not affected by disease subgroup and individual TNFi. Sensitivity analysis showed the treatment effects of TNFi versus placebo were consistent with TNFi versus controls, suggesting the results of the study were robust. The funnel plot of SPARCC score at SIJ based on TNFi versus control in double-blind phase was asymmetric, suggesting there might have potential publication bias. Conclusion TNFi are effective to treat SpA patients and delay MRI progression which are assessed by SPARCC score and treatment effect is consistent among disease subgroups and individual TNFi. References [1] Baraliakos X, Listing J, Fritz C, et al. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years–early clinical response predicts long-term outcome. Rheumatology (Oxford). 2011; 50(9):1690–9. [2] Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir autoimmun. 2010;11:180–210. [3] Wanders a, van der Heijde D, Landewe R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52(6):1756-65. [4] Poddubnyy D, Rudwaleit M, Haibel H, et al.Effect of nonsteroidal antiinflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis inception Cohort. Ann Rheum Dis. 2012;71:1616-22. [5] Puhakka KB, Jurik aG, Schiottz-Christensen B, et al. Magnetic resonance imaging of sacroiliitis in early seronegative spondylarthropathy. Abnormalities correlated to clinical and laboratory findings. Rheumatology (Oxford). 2004;43(2):234–7. Disclosure of interests None declared

Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey

Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network

Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry

Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network

Real-World Adherence and Drug Survival of Biologics among Patients with Ankylosing Spondylitis

Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study

Factors associated with cause-specific discontinuation of long-term anti-tumor necrosis factor agent use in patients with ankylosing spondylitis: a retrospective cohort study

Long‐term follow‐up of anti‐infliximab antibodies in radiographic axial spondyloarthritis patients: a marker of drug survival and tapering

AB0662 Indirect Comparison of TNF Inhibitors for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials

THU0399 Tapering Therapy of Tnf-Inhibitor for Mri Changes in Spondyloarthritis

Sex differences in patient-reported outcomes and the association with clinical factors in axial spondyloarthritis patients treated with tumour necrosis factor inhibitors

The long-term persistence of tumor necrosis factor inhibitors in patients with moderate to severe immune-mediated rheumatic diseases: A nation-wide, population-based real-world study

Efficacy, safety and cost per responder of biologics in the treatment of non-radiographic axial spondyloarthritis

Site-specific assessment of spinal radiographic progression improves detection of TNF blocker-associated disease modification in axial spondyloarthritis: longitudinal observational data from the Swiss Clinical Quality Management Registry

Improvement of bone mineral density and new vertebral fractures during 8 years of TNF-α inhibition in patients with axial spondyloarthritis

Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on the progression of structural damage in the spine over 2 years in patients with radiographic axial spondyloarthritis from the randomised-controlled CONSUL trial

AB0702 TREATMENT EFFECT OF TUMOR NECROSIS FACTOR A INHIBITORS ON MAGNETIC RESONANCE IMAGING PROGRESSION IN PATIENTS WITH SPONDYLOARTHRITIS: A META-ANALYSIS

Sacroiliac radiographic progression over 10 years in axSpA: data from the DESIR inception cohort

The Retention Rate and Safety of Secukinumab as a First-Line Biologic Agent in Axial Spondyloarthritis Compared to a First Tumor Necrosis Factor (TNF) Inhibitor: A Real-World, Longitudinal Study

The Clinical and MRI Effect of TNF- Inhibitors in Spondyloarthritis Patients With Hip Involvement: A Real-World Observational Clinical Study

Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study